Alnylam Pharmace. buy BMO Capital Markets
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -28.89%. This prediction currently runs until 05.09.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.651% | -0.651% |
| iShares Core DAX® | -1.104% | -6.084% |
| iShares Nasdaq 100 | 0.328% | 2.327% |
| iShares Nikkei 225® | -1.082% | -7.987% |
| iShares S&P 500 | -0.055% | 0.880% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.
Alnylam Pharmace.
24.06.25
24.06.26
13.03.26
Alnylam Pharmace.
24.06.24
24.06.25
25.06.25
Alnylam Pharmace.
27.03.24
27.03.25
28.03.25

